Pelthos TherapeuticsPTHS -0.62%8 Days Payable is 249.07 as of Mar. 2026, which is 162% above its 10-year median of 95.16. GuruFocus rates PTHS with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 706 Biotechnology companies, Pelthos Therapeutics ranks better than 56.8% on this metric.
The historical rank and industry rank for Pelthos Therapeutics's Days Payable or its related term are showing as below:
PTHS'
s Days Payable Range Over the Past 10 Years
Min: 95.16 Med: 95.16 Max: 148.09
Current: 148.09
During the past 6 years, Pelthos Therapeutics's highest Days Payable was 148.09. The lowest was 95.16. And the median was 95.16.
PTHS's Days Payable is ranked better than 56.8% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs PTHS: 148.09
Pelthos Therapeutics's Days Payable
increased
from Mar. 2025 (0.00) to Mar. 2026 (249.07).
It may suggest that Pelthos Therapeuticsdelayed paying its suppliers.
Pelthos Therapeutics Days Payable Related Terms
Pelthos Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Pelthos Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pelthos Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pelthos Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pelthos Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Pelthos Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pelthos Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pelthos Therapeutics (PTHS) has a Days Payable of 249.07 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pelthos Therapeutics and its competitors. This is 162% above median its historical median of 95.16. Over the past decade, Pelthos Therapeutics' Days Payable has ranged from 95.16 to 148.09. According to the industry distribution chart, Pelthos Therapeutics ranks #305 out of 706 companies in the Biotechnology industry, placing it in the top 43.2%.
Is Pelthos Therapeutics' Days Payable too high?
Pelthos Therapeutics' current Days Payable of 249.07 is 162% above median its 10-year median of 95.16. Over the past 10 years, this metric has ranged from a low of 95.16 to a high of 148.09. The Biotechnology industry median Days Payable is 113.56. Pelthos Therapeutics' value of 249.07 is 119.3% above this industry median. Based on the distribution chart, Pelthos Therapeutics ranks #305 out of 706 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Pelthos Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Pelthos Therapeutics' Days Payable compare to CGTX and BDTX?
According to the Biotechnology industry distribution chart, Pelthos Therapeutics ranks #305 out of 706 companies for Days Payable. This puts Pelthos Therapeutics in the upper half of its industry. The industry median Days Payable is 113.56. Pelthos Therapeutics' value of 249.07 is 119.3% above this benchmark. Historically, Pelthos Therapeutics' own Days Payable has ranged from 95.16 to 148.09 over the past decade. While the company's 10-year median is 95.16 vs. the industry median of 113.56, Pelthos Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pelthos Therapeutics's current Days Payable of 249.07 is 119.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pelthos Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pelthos Therapeutics's current Days Payable is 249.07, which is 162% above median its own 10-year median of 95.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pelthos Therapeutics stock overvalued right now?
Pelthos Therapeutics (PTHS) has a current Days Payable of 249.07. The current Days Payable is 249.07, which is 162% above median its 10-year median of 95.16 and 119.3% above the Biotechnology industry median of 113.56. Pelthos Therapeutics' overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pelthos Therapeutics (PTHS), the current Days Payable is 249.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
8GF Score
Get the complete analysis for PTHS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTHS has been successfully added to your 
